Ghayas C. Issa

5 days ago | nature.com | Alex Bataller |Hannah Goulart |Ghayas C. Issa |Courtney DiNardo |Tapan M Kadia |Ian Bouligny | +12 more

AbstractAcute myeloid leukemia (AML) with KMT2A rearrangement (KMT2Ar) has poor outcomes. We analyzed 1,611 patients with AML and 4.3% demonstrated rearrangements in KMT2A. Signaling-related genes (NRAS 30%, KRAS 23% and FLT3-TKD 16%) were the most frequently mutated in patients with KMT2Ar AML.

1 month ago | nature.com | Mahesh Swaminathan |Courtney DiNardo |Naveen Pemmaraju |Guillermo Garcia-Manero |Ghayas C. Issa |Gautam Borthakur | +9 more

To the Editor:The advent of VEN (VEN) has changed the treatment paradigm of acute myeloid leukemia (AML). Currently, venetoclax (VEN), in combination with a hypomethylating agent (HMA), is approved for the treatment of adult patients with AML unsuitable for intensive chemotherapy or frontline treatment of patients ≥75 years [1].

1 month ago | nature.com | Alex Bataller |Koji Sasaki |Danielle Hammond |Mahesh Swaminathan |Ghayas C. Issa |Nicholas Short | +6 more

AbstractHypomethylating agents (HMA) are indicated in the treatment of higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The combination of hypomethylating agents with venetoclax (Ven) has demonstrated promising results in these diseases, although randomized clinical trials are needed for validation.

2 months ago | nature.com | Courtney DiNardo |Wei-Ying Jen |Koichi Takahashi |Tapan M Kadia |Sanam Loghavi |Patrick K. Reville | +19 more

AbstractIntensive chemotherapy remains the standard for newly diagnosed (ND) acute myeloid leukemia (AML); however, relapse risk remains high. Additionally, most patients with relapsed/refractory (RR) AML have poor outcomes. We report the long-term experience of 138 patients, 77 ND and 61 RR, treated with FLAG-IDA in combination with venetoclax.